Long-term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I

Eur J Haematol. 2004 Nov;73(5):380-3. doi: 10.1111/j.1600-0609.2004.00310.x.

Abstract

Interferon has been shown to be an effective treatment of congenital dyserythropoiesis type I (CDA-I), but the optimal dose and the feasibility of this treatment remains to be determined. Here, in a 9-yr follow-up of a single patient, we show that interferon remains active during such a long period. The optimal dose of conventional alpha interferon could be evaluated at 2 million units twice a week. Pegylated interferon could be used as well at a dose of 30 microg/wk. During interferon treatment, serum and erythrocyte ferritin levels decreased progressively, and remained inversely correlated with haemoglobin levels. On repeated liver biopsies, iron overload could be normalized. Low dose interferon is a long-term treatment of CDA-I, and allows a significant decrease in iron overload, that could be interesting even in patients who are only moderately anaemic.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anemia, Dyserythropoietic, Congenital / drug therapy*
  • Biopsy
  • Erythrocytes / chemistry
  • Female
  • Ferritins / blood
  • Hemoglobins / analysis
  • Humans
  • Interferon-alpha / administration & dosage*
  • Iron Overload / prevention & control*
  • Liver / chemistry
  • Time Factors

Substances

  • Hemoglobins
  • Interferon-alpha
  • Ferritins